Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Groups Dislike FDA-Recommended Trial Designs For Low-Glucose Suspend Systems

This article was originally published in The Gray Sheet

Executive Summary

FDA’s recommended trial designs for early versions of “artificial pancreas” devices for type 1 diabetes patients are overly burdensome and will hinder development in the space, device makers and clinical societies say.

You may also be interested in...

FDA Releases Draft Guidance On Closed-Loop Artificial Pancreas Devices

Draft issued Dec. 1 emphasizes flexible clinical trial designs to support approval of glucose monitor/insulin pump combination devices that work together without the need for patient intervention.

News In Brief

Regulatory News In Brief

Contura’s Aquamid advisory panel delayed

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts